Form 4: Dare Bioscience Chief Accounting Officer Awarded Stock Options

Dare Bioscience's Chief Accounting Officer, MarDee Haring-Layton, was granted 38,000 stock options on January 28, 2025.

Summary

• MarDee Haring-Layton, Chief Accounting Officer of Dare Bioscience, Inc., was granted 38,000 stock options on January 28, 2025.
• The options have an exercise price of $3.27 per share.
• The options vest in 48 equal monthly installments starting one month after the grant date, contingent on continuous service to the company.
• The options expire on January 28, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to positive.

Positives

• The grant of stock options aligns the Chief Accounting Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the officer.

Risks

• The value of the stock options is dependent on the future performance of Dare Bioscience's stock price.
• If the stock price does not exceed the exercise price of $3.27, the options will have no value.

Industry Context

Stock option grants are a common form of compensation for executives in the biotechnology industry, aligning their interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice in the biotech industry to incentivize and retain key personnel.
• The vesting schedule of 48 months is typical for executive stock options.
• The exercise price of $3.27 is dependent on the current market price of DARE stock and is not directly comparable to other companies without knowing their stock price and option grant terms.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Accounting Officer to contribute to the company's success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, equity compensation, insider trading, Dare Bioscience, MarDee Haring-Layton, Chief Accounting Officer